Special Issue "Economics of New Drug Development and Approval"


A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601).

Deadline for manuscript submissions: closed (14 February 2014)

Special Issue Editor

Guest Editor
Dr. Joseph A. DiMasi
Economic Analysis, Tufts Center for the Study of Drug Development, Tufts Medical School, Tufts University, 75 Kneeland Street, Suite 1100, Boston, MA 02109, USA
Website: http://csdd.tufts.edu/
E-Mail: joseph.dimasi@tufts.edu
Phone: +1 617 636 2116
Interests: biopharmaceutical R&D costs; risks; and time; drug and biologics regulation; innovation incentives; economic structure of the biopharmaceutical industry

Special Issue Information

Dear Colleagues,

The development of new drugs is an important source of medical innovation. It is also exceptionally lengthy, risky, and costly. The economics of the pharmaceutical and biotechnology industries are driven, to a large extent, by these realities. That has led to numerous regulatory programs and policies designed with the hope that the regulatory approval process will be streamlined while maintaining review standards and also that the development of important new therapies will be facilitated. Industry, for its part, has experimented in recent years with reorganizing internal R&D activities and developing new models of interacting with academic medical centers, non-profit institutes, government agencies, and with each other. This issue welcomes articles on policies, programs, and processes that can affect incentives to develop new drugs and biologics, and generally on development, regulatory, promotional, and market processes that impact the economics of new drug development and approval.

Dr. Joseph A. DiMasi
Guest Editor


Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs).


  • pharmaceutical R&D processes
  • drug regulatory approval policies
  • incentives for pharmaceutical innovation
  • metrics on new drug development and approval
  • medical and economic impact of new drug development

Published Papers (2 papers)

Int. J. Environ. Res. Public Health 2014, 11(5), 5069-5080; doi:10.3390/ijerph110505069
Received: 20 February 2014; in revised form: 29 April 2014 / Accepted: 30 April 2014 / Published: 12 May 2014
Show/Hide Abstract | PDF Full-text (187 KB) | HTML Full-text | XML Full-text

by , ,  and
Int. J. Environ. Res. Public Health 2013, 10(9), 4339-4351; doi:10.3390/ijerph10094339
Received: 25 July 2013; in revised form: 9 September 2013 / Accepted: 10 September 2013 / Published: 13 September 2013
Show/Hide Abstract | PDF Full-text (225 KB) | HTML Full-text | XML Full-text

Last update: 15 May 2013

Int. J. Environ. Res. Public Health EISSN 1660-4601 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert